NDAORALFILM
Approved
Apr 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
RIZAFILM (rizatriptan benzoate) by Jubilant Therapeutics is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache (), migraine. First approved in 2023.
Drug data last refreshed Yesterday
Mechanism of Action
5-HT 1B/1D receptors. MAXALT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Indications (3)
Worked on RIZAFILM at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.